TCRT Stock Soars After Velaris Deal And $350M Funding Wave

Alaunos Therapeutics Inc. surged as pivotal cancer trial progress fueled optimism, and its stocks have been trading up by 33.13 percent.

Spot the Next Big Runner

Click Here for a Millionaire's POV on Trading TCRT

SUBSCRIBE FOR ALERTS

JOIN 50,000+ ACTIVE TRADERS

Key Takeaways

Alaunos Therapeutics completed the Velaris Therapeutics acquisition, adding ActRII-Fc ligand traps and biologics for pulmonary arterial hypertension and related cardiopulmonary diseases.
The company raised about $350M via a private placement of Series C non‑voting convertible preferred stock, extending its cash runway into 2029.
Following the Velaris deal and financing, TCRT shares exploded between roughly 126% and 225% on extremely heavy trading volume.
Separate SEC filings showed Fairmount Funds bought a 19.99% stake in TCRT and aims to control four of five board seats, pending shareholder approval.

Live Update At 07:46:41 EDT: On Monday, October 19, 2026 Alaunos Therapeutics Inc. stock [NASDAQ: TCRT] is trending up by 33.13%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

TCRT has been trading like a biotech on steroids. In late September, Alaunos Therapeutics sat under $1, closing at $0.8875 on 2026/09/30. By 2026/10/12, TCRT closed at $1.05. The real fireworks hit on 2026/10/13, when news of the Velaris Therapeutics acquisition and the $350M private placement sent the stock from a $1.73 open to a $3.03 close, with an intraday high of $4.32.

The next day, TCRT spiked to $4.40 before fading to $2.07, showing classic parabolic blowoff action that veteran traders recognize. Recent closes in the mid‑$2 range still leave Alaunos up several hundred percent from pre‑deal levels, but well off the spike highs. Intraday, the 5‑minute chart shows a grind around $2.60–$2.70 before another push over $3.50 in premarket — plenty of range for active trading.

More Breaking News

Fundamentally, Alaunos Therapeutics is still tiny. Latest quarterly revenue is just $5,000, with a pretax margin around -3,348% and a price‑to‑sales ratio near 957, classic early‑stage biotech territory. Cash was only $124,000 at the last report, a current ratio of 0.8, and heavy losses. That is exactly why the $350M capital raise tied to Velaris matters so much for TCRT traders following the story now.

Why Traders Are Watching TCRT’s Velaris Pivot

TCRT isn’t just bouncing on hot money; it is being repriced off a fundamental pivot. Alaunos Therapeutics closed the acquisition of Velaris Therapeutics, picking up a pipeline of ActRII‑Fc ligand traps and biologics aimed at pulmonary arterial hypertension and related cardiopulmonary diseases. For a micro‑cap that previously had minimal revenue and major losses, this gives traders a fresh narrative and real drug candidates to track.

The kicker is the financing. Alaunos raised about $350M via a private placement of Series C non‑voting convertible preferred stock, a structure that brings in serious capital while avoiding immediate common‑share voting dilution. Management guided that this cash should fund operations into 2029 and push multiple Velaris‑originated candidates through proof‑of‑concept and initial regulatory filings. In trader terms, TCRT just bought itself a multi‑year runway to try to create value.

The market’s reaction shows how dramatic this reset is. After the Velaris deal and funding news, TCRT ran between roughly 126% and 225% on extremely heavy volume. That type of move tells you big money is repositioning, not just day traders scalping a headline. Still, the intraday swings — ripping to the $4s, then closing near $2 — remind everyone that Alaunos Therapeutics remains a high‑volatility biotech.

Layered on top is the governance angle. SEC filings revealed Fairmount Funds has built a 19.99% stake in Alaunos Therapeutics and wants four of five board seats, subject to shareholder approval. That is near‑control, activist‑style behavior. For TCRT traders, it signals that a sophisticated fund sees enough upside in this Velaris pivot to fight for the steering wheel, even if that creates some boardroom drama down the road.

Conclusion

TCRT is a textbook example of how fast sentiment can flip in small‑cap biotech when the story changes. A few weeks ago, Alaunos Therapeutics was a sub‑$1 name with $124,000 in cash and steep losses. Now, with the Velaris Therapeutics acquisition, a $350M private placement, and a new pipeline focused on pulmonary arterial hypertension, traders are treating TCRT as a completely different animal. The chart reflects that: multi‑hundred‑percent moves, thick volume, and wide intraday ranges.

That does not erase the risk. Alaunos Therapeutics still needs to execute on clinical trials, manage its new capital base, and navigate an activist‑leaning shareholder in Fairmount Funds seeking control of four board seats. Any stumble in data, financing terms, or governance could hit TCRT hard. At the same time, the extended cash runway into 2029 and multiple shots on goal give the ticker real optionality that wasn’t there before.

For active traders who live on volatility and catalysts, TCRT now checks both boxes. The key is to respect the range and avoid marrying the stock. As Tim Sykes loves to say, “The market doesn’t care about your opinion, only your discipline.” As Tim Bohen, lead trainer with StocksToTrade says, “I focus on momentum that’s visible right now. Speculation on future moves is outside my playbook.”. With Alaunos Therapeutics, the setup rewards those who plan their trades, react to the price action, and cut losses fast when the story or the chart shifts — while remembering this is educational research, not a signal to buy or sell.

This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.

Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.

Check out our quick startup guide for new traders!

Ready to build your watchlists? Check out these curated lists:

Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.

Start Your Trial Now!